PARP inhibitors are a promising therapy in cancer treatment, having already demonstrated their beneficial effects in the treatment of ovarian cancer patients with specific deficiencies in homologous recombination-mediated DNA repair. The gene discussed is PARP1; the disease is ovarian carcinoma.